ABVC Seeks Shareholder Approval for 6.6M Share Land Acquisition and New Equity Plan

summarizeSummary

ABVC BioPharma's revised proxy seeks approval for a land acquisition that could issue up to 6.6 million shares to a related party, plus a new equity plan and ratification of prior awards, against a backdrop of financial distress.

check_boxKey Events · Corporate Governance and Compliance · ABVC

• Land Acquisition Share Issuance

  Proposal 3 authorizes issuance of up to 6,638,591 shares at a price not less than $1.00 per share to acquire land in Taoyuan and Hualien, Taiwan, from Board member Shuling Jiang.

• Related-Party Transaction

  The seller of the properties is Ms. Shuling Jiang, a current Board member, making this a related-party transaction requiring corporate approval processes.

• New Equity Incentive Plan

  Proposal 1 seeks approval of the 2026 Equity Incentive Plan with an initial award pool of 1,169,201 shares plus 15% of outstanding shares, and an annual 5% evergreen provision.

• Ratification of Prior Awards

  Proposal 2 ratifies 600,000 shares granted to two advisors since February 16, 2026, at 50,000 shares per advisor per month for six months.

auto_awesomeAnalysis · ABVC · Life Sciences

ABVC BioPharma is asking shareholders to approve issuing up to 6,638,591 shares at a minimum of $1.00 per share to acquire land in Taiwan from a related party, Board member Shuling Jiang. The company also seeks approval for a new 2026 Equity Incentive Plan and ratification of 600,000 shares already granted to two advisors. This comes amid a going-concern warning and a wider working capital deficit disclosed in the Q2 10-Q filed the same day, raising concerns about dilution and governance.